These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28747178)

  • 1. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.
    Durnaś B; Piktel E; Wątek M; Wollny T; Góźdź S; Smok-Kalwat J; Niemirowicz K; Savage PB; Bucki R
    BMC Microbiol; 2017 Jul; 17(1):167. PubMed ID: 28747178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Core-shell magnetic nanoparticles display synergistic antibacterial effects against
    Niemirowicz K; Piktel E; Wilczewska AZ; Markiewicz KH; Durnaś B; Wątek M; Puszkarz I; Wróblewska M; Niklińska W; Savage PB; Bucki R
    Int J Nanomedicine; 2016; 11():5443-5455. PubMed ID: 27799768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.
    Wnorowska U; Niemirowicz K; Myint M; Diamond SL; Wróblewska M; Savage PB; Janmey PA; Bucki R
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3808-15. PubMed ID: 25870055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications.
    Wnorowska U; Fiedoruk K; Piktel E; Prasad SV; Sulik M; Janion M; Daniluk T; Savage PB; Bucki R
    J Nanobiotechnology; 2020 Jan; 18(1):3. PubMed ID: 31898542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.
    Niemirowicz K; Durnaś B; Tokajuk G; Piktel E; Michalak G; Gu X; Kułakowska A; Savage PB; Bucki R
    Sci Rep; 2017 Jul; 7(1):4610. PubMed ID: 28676673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.
    Durnaś B; Wnorowska U; Pogoda K; Deptuła P; Wątek M; Piktel E; Głuszek S; Gu X; Savage PB; Niemirowicz K; Bucki R
    PLoS One; 2016; 11(6):e0157242. PubMed ID: 27315208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells.
    Niemirowicz K; Prokop I; Wilczewska AZ; Wnorowska U; Piktel E; Wątek M; Savage PB; Bucki R
    Int J Nanomedicine; 2015; 10():3843-53. PubMed ID: 26082634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.
    Niemirowicz K; Surel U; Wilczewska AZ; Mystkowska J; Piktel E; Gu X; Namiot Z; Kułakowska A; Savage PB; Bucki R
    J Nanobiotechnology; 2015 May; 13():32. PubMed ID: 25929281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.
    Leszczyńska K; Namiot A; Fein DE; Wen Q; Namiot Z; Savage PB; Diamond S; Janmey PA; Bucki R
    BMC Microbiol; 2009 Sep; 9():187. PubMed ID: 19728885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of ceragenins as a potential treatment for urinary tract infections.
    Wnorowska U; Piktel E; Durnaś B; Fiedoruk K; Savage PB; Bucki R
    BMC Infect Dis; 2019 May; 19(1):369. PubMed ID: 31046689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stiffening of bacteria cells as a first manifestation of bactericidal attack.
    Pogoda K; Piktel E; Deptuła P; Savage PB; Lekka M; Bucki R
    Micron; 2017 Oct; 101():95-102. PubMed ID: 28683405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of antimicrobial peptides and ceragenins against Legionella pneumophila.
    Birteksoz-Tan AS; Zeybek Z; Hacioglu M; Savage PB; Bozkurt-Guzel C
    J Antibiot (Tokyo); 2019 May; 72(5):291-297. PubMed ID: 30755738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.
    Bucki R; Niemirowicz K; Wnorowska U; Byfield FJ; Piktel E; Wątek M; Janmey PA; Savage PB
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6274-82. PubMed ID: 26248361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.
    Bucki R; Namiot DB; Namiot Z; Savage PB; Janmey PA
    J Antimicrob Chemother; 2008 Aug; 62(2):329-35. PubMed ID: 18456648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections.
    Leszczynska K; Namiot D; Byfield FJ; Cruz K; Zendzian-Piotrowska M; Fein DE; Savage PB; Diamond S; McCulloch CA; Janmey PA; Bucki R
    J Antimicrob Chemother; 2013 Mar; 68(3):610-8. PubMed ID: 23134677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms.
    Bozkurt Guzel C; Oyardi O; B Savage P
    J Chemother; 2018; 30(6-8):332-337. PubMed ID: 30663553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections.
    Leszczyńska K; Namiot A; Cruz K; Byfield FJ; Won E; Mendez G; Sokołowski W; Savage PB; Bucki R; Janmey PA
    J Appl Microbiol; 2011 Jan; 110(1):229-38. PubMed ID: 20961363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Effectiveness of Ceragenins against
    Karasiński M; Wnorowska U; Daniluk T; Deptuła P; Łuckiewicz M; Paprocka P; Durnaś B; Skłodowski K; Sawczuk B; Savage PB; Piktel E; Bucki R
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiofilm activities of ceragenins and antimicrobial peptides against fungal-bacterial mono and multispecies biofilms.
    Hacioglu M; Oyardi O; Bozkurt-Guzel C; Savage PB
    J Antibiot (Tokyo); 2020 Jul; 73(7):455-462. PubMed ID: 32203127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins.
    Epand RF; Pollard JE; Wright JO; Savage PB; Epand RM
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3708-13. PubMed ID: 20585129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.